Quick Takeaways: Why It Matters? VETARYS and Antigenesis are advancing a potential canine cancer immunotherapy that adapts human oncology approaches for veterinary use. A subcutaneous formulation suitable for primary-care clinics could broaden access beyond specialist cen...
Quick Takeaways: Why It Matters? OST-HER2’s potential conditional licensure could give OSAH a first-mover advantage in HER2-targeted canine osteosarcoma, an area with limited treatment options. A 2027 launch could establish a differentiated oncology franchise, while validating ...
Quick Takeaways: Why It Matters? Dechra has launched Laverdia (verdinexor tablets), the first and only FDA‑approved oral treatment for dogs with lymphoma, enabling at‑home therapy that can start on Day 1 after diagnosis. Canine lymphoma is one of the most common cancers i...
Quick Takeaways: Why It Matters? By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing. Bundling mast cell detection at no extra c...
